New combo aims to boost Radiation's power against tough pancreatic cancer
NCT ID NCT06141031
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a drug called TTI-101 combined with a precise type of radiation (SBRT) in 18 people with pancreatic cancer that is borderline resectable or locally advanced. The goal is to see if the combination is safe and can improve how long patients live without the cancer growing. The drug works by blocking a protein that may help tumors resist radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TTI-101 (a drug that blocks STAT3 protein) and stereotactic body radiation therapy (SBRT, a precise type of radiation)
What this could lead to
If this works, it could point toward a new combination treatment that improves survival for people with pancreatic cancer that hasn't spread.
What could go wrong
This is a very early, small Phase 1 trial with only 18 participants, so it's mainly checking safety and dosing. The treatment may not improve survival or could cause unexpected side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado
COMPLETEDAurora, Colorado, 80045, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact